FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

Paul Modest, Dominik; M. Martens, Uwe; Riera‐Knorrenschild, Jorge; Greeve, Jobst; Florschütz, Axel; Weßendorf, Swen; J. Ettrich, Thomas; Kanzler, Stephan; Nörenberg, Dominik; Ricke, Jens; Seidensticker, Max; Held, Swantje; Buechner-Steudel, Petra; Atzpodien, Jens; Heinemann, Volker; Seufferlein, Thomas; Tannapfel, Andrea; Reinacher‐Schick, Anke; Geißler, Michael

doi:10.1200/jco.19.01340

Public

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

Published in Journal of Clinical Oncology • Oct 14, 2019

Authors:

Dominik Paul Modest

Uwe M. Martens

Jorge Riera‐Knorrenschild

Abstract

PURPOSE This trial investigated the addition of panitumumab to triplet chemotherapy with fluorouracil/folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI) in a two-to-one randomized, controlled, open-label, phase II trial in patients with untreated RAS wild-type (WT) metastatic colorectal cancer. P...

Subject

Panitumumab

Medicine

Irinotecan

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!